[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-384299-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-384299-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","association-of-whsc1nsd2-and-t-cell-infiltration-with-prostate-cancer-metastasis-and-prognosis","Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis","","Study evaluates the feasibility of NSD2 as an immunotherapeutic target in prostate cancer by measuring NSD2 expression across benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and prostate cancer, including metastatic castration-resistant cases. Single-cell RNA sequencing, GSEA, and IOBR software link NSD2 to tumor microenvironment pathways. NSD2 positivity increases from BPH to PCa, associates with CD4+ TIL infiltration, and stratifies patients based on OS, while PSA and CD4+ TILs predict bone metastasis risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/association-of-whsc1nsd2-and-t-cell-infiltration-with-prostate-cancer-metastasis-and-prognosis/384299/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/association-of-whsc1nsd2-and-t-cell-infiltration-with-prostate-cancer-metastasis-and-prognosis/384299.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study regarding NSD2 in prostate cancer?","Question",{"text":63,"@type":64},"To assess whether NSD2 is feasible as an immunotherapeutic target in prostate cancer by linking its expression to immune infiltration and patient outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was NSD2 expression evaluated across prostate disease stages?",{"text":68,"@type":64},"NSD2 expression patterns were assessed by immunohistochemistry in BPH, PIN, and prostate cancer, including metastatic castration-resistant prostate cancer cases.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune relationships were found between NSD2 and TIL subsets?",{"text":72,"@type":64},"Higher NSD2 expression correlated positively with CD4+ tumor-infiltrating lymphocytes and negatively with CD8+ tumor-infiltrating lymphocytes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},384299,1790319029,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAssociation of WHSC1/NSD2 and T‑cell infiltration with prostate cancer metastasis and prognosis  \nQiheng Li1, Jiang Zhu2, Yang Zhang3, Yun Pan1, Zhengjin Li1, Min Wang1, Yixuan Gao1, Dongmei Feng1, Xiaoyong He4 & Chunmei Zhang1*  \nProgress in immunotherapy for prostate cancer (PCa) lags that for other cancers, mainly because of limited immune infiltration in PCa. This study aimed to assess the feasibility of NSD2 as an immunotherapeutic target in PCa. Immunohistochemistry was performed to evaluate the expression pattern of NSD2 in 34 cases of benign prostatic hyperplasia (BPH), 36 cases of prostatic intraepithelial neoplasia (PIN), and 57 cases of PCa, including 19 cases of metastatic castration‑resistant prostatic cancer (mCRPC). Single‑cell RNA sequencing and gene set enrichment analysis (GSEA) were used to correlate NSD2 with certain downstream pathways. Furthermore, the Immuno‑Oncology‑Biological‑ Research (IOBR) software package was used to analyze the potential roles of NSD2 in the tumor microenvironment. We found that the positive expression rate of NSD2 increased progressively in BPH, PIN and PCa. mCRPC had the highest staining intensity for NSD2 . High NSD2 expression was positively correlated with the infiltration level of CD4+ tumor‑infiltrating lymphocytes (TILs) and negatively correlated with that of CD8+ TILs. Importantly, a new immune classification based on NSD2 expression and CD4+ TILs and CD8+ TILs was successfully used to stratify PCa patients based on OS.PSA and CD4+ TILs are independent risk factors for PCa bone metastasis. This study demonstratesa novel role for NSD2 in defining immune infiltrate on in PCa and highlights the great potential for its application in immunotherapy response evaluation for prostate malignancies.  \nProstate cancer (PCa) is the most commonly diagnosed cancer in men and is one of the leading causes of cancerrelated death worldwide 1. PCa growth is intrinsically driven by the androgen receptor (AR), and androgen deprivation therapy (ADT), which blocks androgen signaling, is a common therapeutic intervention aimed at reducing tumor size2. ADT induces the formation of a complex proinflammatory tumor microenvironment. This pro-inflammatory microenvironment is apparent in the early post castration period, but the majority of PCa cases ultimately progress to castration-resistant prostatic cancer3. Castration-resistant prostate cancer (CRPC) is incurable and has a poor prognosis as it often metastasizes to bones, lymph nodes or bladders. This advanced stage is called mCRPC. However, once recurrence and distant metastasis occur, which means that the patient is resistant to current treatment, the disease progresses rapidly, eventually leading to death4. For localized PCa, radical prostatectomy with/without radiation is the main therapeutic strategy, but treatment options for CRPC have been limited for decades5. In light of this, there is a pressing need to assess new and existing immunotherapy regimens to increase treatment efficacy.  \nWith the intensive investigation of the immune microenvironment within tumors, it is evident that immune check‐point inhibitors (ICIs), which counteract the functional suppression of CD8+ cytotoxic T cells (CTLs), have produced some unprecedented long‐lasting responses in cancer immunotherapy. ICI treatment is especially effective in “hot” tumors containing high numbers of CTLs6. However, the efficacy of ICIs in treating PCa has been disappointing7. A better understanding of PCa TILs and their microenvironment may improve our ability to target PCa immunologically. Many reports provide evidence of the favorable prognostic implications value of TILs in many cancers, but the role of TILs in PCa and their composition remain controversial8,9.  \nNSD2 is a histone methyltransferase, elevated NSD2 expression correlates with worse prognosis in a number of cancers due to its oncogenic role","cbCaiakEdkSFVwbl","https://ap.wps.com/l/cbCaiakEdkSFVwbl","pdf",7469130,"English","# Background and rationale\n## Prostate cancer progression and immune infiltration challenges\n## Immune checkpoint inhibition and TIL controversy\n# NSD2 biology and study design\n## Histone methyltransferase role\n## Expression analysis across disease stages\n## Single-cell RNA sequencing and pathway analysis\n## Tumor microenvironment modeling with IOBR\n# Key findings and clinical implications\n## NSD2 expression trends and staining in mCRPC\n## Correlations with CD4+ and CD8+ TILs\n## Immune classification for OS stratification\n## Risk factors for bone metastasis","[{\"question\":\"What is the main goal of the study regarding NSD2 in prostate cancer?\",\"answer\":\"To assess whether NSD2 is feasible as an immunotherapeutic target in prostate cancer by linking its expression to immune infiltration and patient outcomes.\"},{\"question\":\"How was NSD2 expression evaluated across prostate disease stages?\",\"answer\":\"NSD2 expression patterns were assessed by immunohistochemistry in BPH, PIN, and prostate cancer, including metastatic castration-resistant prostate cancer cases.\"},{\"question\":\"What immune relationships were found between NSD2 and TIL subsets?\",\"answer\":\"Higher NSD2 expression correlated positively with CD4+ tumor-infiltrating lymphocytes and negatively with CD8+ tumor-infiltrating lymphocytes.\"}]","Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis | PDF",1790262093]